Karen Bartlett

  • Litigation: Post-Mensing sands still shifting on generic design defect claims

    Pharmaceutical companies anticipate that the next several months will provide needed clarity and consistency regarding the pre-emption landscape for manufacturers of generic pharmaceutical products, with the Supreme Court scheduled to hear oral argument on March 19 in Mutual Pharmaceutical Co. Inc. v. Bartlett.

  • Supreme Court takes up design-defect drug case

    The Supreme Court on Friday agreed to review an appeals court’s decision that generic drug manufacturers can face lawsuits over alleged problems in the design of drugs, regardless of federal protections against design-defect claims.

  • Roundup: 1st, 3rd, 5th and D.C. Circuits

    Design defect claims against generic drugs not preempted; Employer owns copyright of computer program worker developed at home; Texas cannot defund Planned Parenthood; Citations under OSHA subject to six-month statute of limitations

Advertisement. Closing in 15 seconds.